

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Galsulfase. [Updated 2024 Aug 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Galsulfase

Revised: August 15, 2024.

CASRN: 552858-79-4

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of galsulfase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 56,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. If the mother requires galsulfase, it is not a reason to discontinue breastfeeding. Until more data are available, use galsulfase with infant careful monitoring during breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Galsulfase

CAS Registry Number

552858-79-4

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Drug Class

Breast Feeding

Lactation

Milk, Human

Enzymes

Enzyme Replacement Therapy

Chondroitinsulfatases